Spark Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$31.3M
Doctors Paid
1,522
Transactions
4,547
2024 Total
$1.9M
Payment Breakdown by Category
Research$15.3M (49.0%)
Royalty/License$13.4M (42.9%)
Consulting$1.1M (3.4%)
Food & Beverage$123,547 (0.4%)
Travel$122,540 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15.3M | 1,169 | 49.0% |
| Royalty or License | $13.4M | 142 | 42.9% |
| Consulting Fee | $1.1M | 325 | 3.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $958,173 | 250 | 3.1% |
| Food and Beverage | $123,547 | 2,168 | 0.4% |
| Travel and Lodging | $122,540 | 438 | 0.4% |
| Grant | $110,106 | 6 | 0.4% |
| Education | $81,741 | 32 | 0.3% |
| Charitable Contribution | $46,100 | 5 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $36,700 | 12 | 0.1% |
Payments by Type
General
$16.0M
3,378 transactions
Research
$15.3M
1,169 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A LONG-TERM FOLLOW-UP STUDY IN SUBJECTS WHO RECEIVED AN ADENOVIRUS-ASSOCIATED VIRAL VECTOR SEROTYPE 2 CONTAINING THE HUMAN RPE65 GENE (AAV2-HRPE65V2, VORETIGENE NEPARVOVEC-RZYL) ADMINISTERED VIA SUBRETINAL INJECTION | $4.4M | 0 | 256 |
| Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors | $1.1M | 0 | 6 |
| GENE TRANSFER, DOSE-FINDING SAFETY, TOLERABILITY, AND EFFICACY STUDY OF SPK-8011 A RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR WITH HUMAN FACTOR VIII GENE IN INDIVIDUALS WITH HEMOPHILIA A | $941,955 | 1 | 59 |
| A POST-AUTHORIZATION, MULTICENTER, LONGITUDINAL, OBSERVATIONAL SAFETY REGISTRY STUDY FOR PATIENTS TREATED WITH VORETIGENE NEPARVOVEC | $766,573 | 0 | 137 |
| A PHASE 12 SAFETY STUDY IN SUBJECTS WITH CHM CHOROIDEREMIA GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VECTOR TO DELIVER THE NORMAL HUMAN CHM GENE AAV2-HCHM TO THE RETINA | $677,667 | 3 | 33 |
| DOSE-FINDING STUDY OF SPK-8016 GENE THERAPY IN PATIENTS WITH HEMOPHILIA A TO SUPPORT EVALUATION IN INDIVIDUALS WITH FVIII INHIBITORS | $578,898 | 4 | 73 |
| A Long-Term Follow-Up Study in Subjects Who Received an Adenovirus-Associated Viral Vector Serotype 2 Containing the Human RPE65 Gene AAV2-hRPE65v2, Voretigene Neparvovec-rzyl Administered Via Subretinal Injection | $541,093 | 0 | 29 |
| A MULTI-CENTER EVALUATION OF THE LONG-TERM SAFETY AND EFFICACY OF SPK-8011 [ADENO-ASSOCIATED VIRAL VECTOR WITH B-DOMAIN DELETED HUMAN FACTOR VIII GENE] IN MALES WITH HEMOPHILIA A | $278,439 | 0 | 84 |
| CHM NATURAL HX | $245,782 | 0 | 29 |
| A LONG-TERM FOLLOW-UP STUDY IN SUBJECTS WHO RECEIVED AN ADENOVIRUS-ASSOCIATED VIRAL VECTOR SEROTYPE 2 CONTAINING THE HUMAN RPE65 GENE AAV2-HRPE65V2, VORETIGENE NEPARVOVEC-RZYL ADMINISTERED VIA SUBRETINAL INJECTION | $228,643 | 0 | 18 |
| A MULTI-CENTER, OBSERVATIONAL STUDY IN MALES WITH HEMOPHILIA A | $225,470 | 0 | 68 |
| PHASE 1/2, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF A SINGLE INTRAVENOUS INFUSION OF SPK-3006 IN ADULTS WITH LATE-ONSET POMPE DISEASE | $222,977 | 2 | 21 |
| A Long-Term Follow-Up Study in Subjects Who Received an Adenovirus-Associated Viral Vector Serotype 2 Containing the Human RPE65 Gene (AAV2-hRPE65v2, Voretigene Neparvovec-rzyl) Administered Via Subretinal Injection | $218,099 | 0 | 25 |
| GENE TRANSFER, DOSE-FINDING SAFETY, TOLERABILITY, AND EFFICACY STUDY OF SPK-8011 [A RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR WITH HUMAN FACTOR VIII GENE] IN INDIVIDUALS WITH HEMOPHILIA A | $161,476 | 1 | 18 |
| A SAFETY AND EFFICACY STUDY IN SUBJECTS WITH LEBER CONGENITAL AMAUROSIS LCA USING ADENO-ASSOCIATED VIRAL VECTOR TO DELIVER THE GENE FOR HUMAN RPE65 TO THE RETINAL PIGMENT EPITHELIUM RPE AAV2-HRPE65V2-301 | $148,150 | 0 | 6 |
| Genetic Analyses of the Ocular Genomics Institute Inherited Retinal Degeneration | $141,291 | 0 | 3 |
| AAV2-HRPE65V2-102; AAV2-HRPE65V2-301; AAV2-HRPE65V2-LTFU-01 | $132,893 | 0 | 17 |
| A MULTI-CENTER, LOW-INTERVENTIONAL STUDY WITH A RETROSPECTIVE COMPONENT IN PARTICIPANTS WITH LATE-ONSET POMPE DISEASE | $131,360 | 0 | 19 |
| A PHASE 1/2 SAFETY STUDY IN SUBJECTS WITH CHM (CHOROIDEREMIA) GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VECTOR TO DELIVER THE NORMAL HUMAN CHM GENE [AAV2-HCHM] TO THE RETINA | $122,832 | 3 | 7 |
| CHOP PENN PSA | $76,442 | 0 | 1 |
| A MULTI-CENTER EVALUATION OF THE LONG-TERM SAFETY AND EFFICACY OF SPK-8011 ADENO-ASSOCIATED VIRAL VECTOR WITH B-DOMAIN DELETED HUMAN FACTOR VIII GENE IN MALES WITH HEMOPHILIA A | $70,302 | 0 | 16 |
| FIX-LONG STUDY A FACTOR IX FIX GENE TRANSFER, MULTI-CENTER EVALUATION OF THE LONG-TERM SAFETY AND EFFICACY STUDY OF SPK-9001 RAAV-SPARK100-HFIX-PADUA IN INDIVIDUALS WITH HEMOPHILIA B | $50,858 | 0 | 20 |
| A LONG-TERM FOLLOW-UP STUDY IN SUBJECTS WITH SEVERE HEMOPHILIA B (FACTOR IX DEFICIENCY) WHO RECEIVED A SINGLE-STRANDED, ADENO-ASSOCIATED PSEUDOTYPE 8 VIRAL VECTOR TO DELIVER THE GENE FOR HUMAN FACTOR IX (AAV8-HFIX19) | $50,773 | 0 | 11 |
| A PHASE 1 SAFETY STUDY IN SUBJECTS WITH SEVERE HEMOPHILIA B FACTOR IX DEFICIENCY USING A SINGLE-STRANDED, ADENO-ASSOCIATED PSEUDOTYPE 8 VIRAL VECTOR TO DELIVER THE GENE FOR HUMAN FACTOR IX | $45,621 | 0 | 8 |
| A Long-Term Follow-Up Study in Subjects with Severe Hemophilia B Factor IX Deficiency Who Received a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX AAV8-hFIX19 | $39,149 | 0 | 10 |
| AAV2-hRPE65v2-102; AAV2-hRPE65v2-301; AAV2-hRPE65v2-LTFU-01 | $38,865 | 0 | 8 |
| A FOLLOW-ON STUDY TO EVALUATE THE SAFETY OF RE-ADMINISTRATION OF ADENO-ASSOCIATED VIRAL VECTOR CONTAINING THE GENE FOR HUMAN RPE65 AAV2-HRPE65V2 TO THE CONTRALATERAL EYE IN SUBJECTS WITH LEBER CONGENITAL AMAUROSIS LCA PREVIOUSLY ENROLLED IN A PHASE 1 STUDY | $36,773 | 0 | 8 |
| A LONG-TERM FOLLOW-UP STUDY IN SUBJECTS WITH SEVER HEMOPHILIA B WHO RECEIVED ADENO-ASSOCIATED VIRAL VECTORS EXPRESSING HUMAN FACTOR IX | $29,989 | 0 | 9 |
| A LONG-TERM FOLLOW-UP STUDY IN SUBJECTS WITH SEVERE HEMOPHILIA B FACTOR IX DEFICIENCY WHO RECEIVED A SINGLE-STRANDED, ADENO-ASSOCIATED PSEUDOTYPE 8 VIRAL VECTOR TO DELIVER THE GENE FOR HUMAN FACTOR IX AAV8-HFIX19 | $28,398 | 0 | 13 |
| PHASE 12, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF A SINGLE INTRAVENOUS INFUSION OF SPK-3006 IN ADULTS WITH LATE-ONSET POMPE DISEASE | $10,954 | 4 | 40 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Lindsey Greene, M.d, M.D | Pediatric Hematology-Oncology | Philadelphia, PA | $9,548 | $0 |
| Bruce Luxon, Md Phd, MD PHD | Internal Medicine | Washington, DC | $9,268 | $0 |
| Shafeeq Ladha, M.d, M.D | Neurology | Phoenix, AZ | $9,129 | $0 |
| Witold Rybka, Md, MD | Hematology & Oncology | Hershey, PA | $8,917 | $0 |
| Maria-Grazia Roncarolo, M.d, M.D | Pediatric Hematology-Oncology | Stanford, CA | $8,840 | $0 |
| Dr. Robert Richardson, Md, Phd, MD, PHD | Neurological Surgery | Boston, MA | $8,645 | $0 |
| Craig Kessler | Hematology & Oncology | Washington, DC | $8,532 | $0 |
| Dr. Russell Lonser, M.d, M.D | Neurological Surgery | Columbus, OH | $8,400 | $0 |
| Dr. Pravin Dugel | Ophthalmology | Phoenix, AZ | $8,325 | $0 |
| Louis Aledort, Md, MD | Hematology | New York, NY | $8,184 | $0 |
| Dawn Decarlo, Od, OD | Low Vision Rehabilitation | Birmingham, AL | $7,801 | $0 |
| Mark Reding, Md, MD | Internal Medicine | Minneapolis, MN | $7,560 | $0 |
| David Rawlings | Pediatric Rheumatology | Seattle, WA | $7,544 | $0 |
| Mazen Dimachkie, M.d, M.D | Neuromuscular Medicine | Kansas City, KS | $7,129 | $0 |
| Angela Weyand, M.d, M.D | Pediatric Hematology-Oncology | Ann Arbor, MI | $7,101 | $0 |
| Dr. Ashkan Abbey, M.d, M.D | Ophthalmology | Dallas, TX | $7,083 | $0 |
| Dr. Eric Nudleman, M.d., Ph.d, M.D., PH.D | Ophthalmology | San Diego, CA | $7,054 | $0 |
| Dr. Matthew Wicklund, M.d, M.D | Neuromuscular Medicine | San Antonio, TX | $6,984 | $0 |
| Manikkam Suthanthiran, Md, MD | Nephrology | New York, NY | $6,908 | $0 |
| Shawn Jobe, M.d, M.D | Pediatric Hematology-Oncology | Lansing, MI | $6,858 | $0 |
| Perry Shieh, Md, MD | Neuromuscular Medicine | Los Angeles, CA | $6,785 | $0 |
| Dr. E Dorsey, M.d, M.D | Neurology | New York, NY | $6,601 | $0 |
| Behzad Najafian, Md, MD | Anatomic Pathology | Seattle, WA | $6,233 | $0 |
| Dr. Krishna Gundabolu, M.d, M.D | Hematology & Oncology | Omaha, NE | $6,222 | $0 |
| Dr. Nigel Key, Md, MD | Hematology & Oncology | Chapel Hill, NC | $6,205 | $0 |
About Spark Therapeutics, Inc.
Spark Therapeutics, Inc. has made $31.3M in payments to 1,522 healthcare providers, recorded across 4,547 transactions in the CMS Open Payments database. In 2024, the company paid $1.9M. The top product by payment volume is LUXTURNA ($15.9M).
Payments were distributed across 71 medical specialties. The top specialty by payment amount is Ophthalmology ($981,540 to 537 doctors).
Payment categories include: Food & Beverage ($123,547), Consulting ($1.1M), Research ($15.3M), Travel & Lodging ($122,540), Royalties ($13.4M).
Spark Therapeutics, Inc. is associated with 1 products in the CMS Open Payments database.